Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 (MIDAS)

This study has been completed.
Tibotec, Inc
Information provided by (Responsible Party):
Babafemi Taiwo, Northwestern University Identifier:
First received: October 8, 2009
Last updated: August 26, 2014
Last verified: August 2014
The objective of this study is to evaluate the safety and efficacy of a novel combination antiretroviral therapy regimen consisting of maraviroc plus darunavir/ritonavir in treatment-naive patients infected with R5-tropic HIV-1. The hypothesis is that in treatment-naive subjects infected with R5-tropic HIV-1, combination antiretroviral therapy with maraviroc plus darunavir/ritonavir is well tolerated and efficacious.

Condition Intervention Phase
HIV-1 Infection
HIV Infections
Drug: maraviroc
Drug: darunavir
Drug: ritonavir
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile

Resource links provided by NLM:

Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Percentage of Participants With Plasma HIV-1 RNA >50 [ Time Frame: 24 weeks ]
    Percentage of participants with confirmed plasma HIV-1 RNA > 50 copies/mL

Secondary Outcome Measures:
  • Percentage of Participants With Virologic Failure or Off Study Treatment Regimen [ Time Frame: 24 weeks ]
    Percentage of participants with virologic failure (confirmed plasma HIV-1 RNA > 50 copies/mL) or off study treatment regimen (composite end point)

  • Percentage of Participants With Plasma HIV-1 RNA >50 Copies/mL [ Time Frame: 48 weeks ]
    Percentage of participants with confirmed plasma HIV-1 RNA level >50 copies/mL

  • Signs/Symptoms or Laboratory Toxicities of Grade 3 or Higher [ Time Frame: 96 weeks ]
    Signs/symptoms or laboratory toxicities of Grade 3 or higher, or of any grade which led to a permanent change or discontinuation of study treatment regimen

  • Drug Resistance Mutations and Co-receptor Tropism Assessed by Trofile ES [ Time Frame: At study entry and at the time of virologic failure ]
  • Drug Adherence, Number of Participants With Missed Doses [ Time Frame: Week 24 ]
    Drug adherence, assessed as number of participants with missed doses over four-day recall

  • Trough Concentrations (Ctrough) of Maraviroc [ Time Frame: 24 hours ]
    Average trough concentration (Ctrough) of maraviroc

  • Median CD4 Count Change From Baseline [ Time Frame: 96 weeks ]
    Median changes from baseline in peripheral CD4+ T-cell count

  • Proportion of Participants With Plasma HIV-1 RNA >50 Copies/mL [ Time Frame: 96 weeks ]
    Proportion of participants with confirmed plasma HIV-1 RNA level >50 copies/mL

Enrollment: 25
Study Start Date: May 2010
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Maraviroc plus darunavir/ritonavir
Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
Drug: maraviroc
150 mg tab by mouth once daily for 96 weeks
Other Name: Selzentry
Drug: darunavir
800 mg tab by mouth once daily for 96 weeks
Other Name: Prezista
Drug: ritonavir
100 mg capsule by mouth once daily for 96 weeks
Other Name: norvir


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA any time prior to study entry
  • Plasma HIV-1 RNA 5, 000 to 500,000 copies/mL obtained within 90 days prior to study entry
  • Exclusive R5 tropism based on enhanced sensitivity Trofile assay done within 90 days prior to entry
  • CD4 cell count > 100 cells/mm3 within 90 days prior to study entry
  • HIV genotype (for RT and protease) performed at any time before study entry (Subjects with single or combination NNRTI or NRTI RAM(s) at screening are permitted)
  • ARV drug-naïve, defined as no previous ARV treatment at any time prior to study entry
  • Negative result from a hepatitis B surface antigen test performed within 90 days prior to study entry
  • Negative result from a hepatitis C antibody test performed within 90 days prior to study entry
  • Laboratory values obtained within 30 days prior to study entry:

    • ANC >=750/mm3
    • Hemoglobin >=10 g/dL
    • Platelets >=50,000/mm3
    • AST (SGOT), ALT (SGPT), and alkaline phosphatase <=5 x ULN
    • Calculated creatinine clearance (CrCl) >=30 mL/min, as estimated by the Cockcroft-Gault equation*
  • Negative serum or urine pregnancy test within 48 hours prior to study entry for women with reproductive potential
  • If participating in sexual activity that could lead to pregnancy, the study subjects with reproductive potential must use one form of contraceptive while receiving protocol-specified medications and for 60 days after stopping the medications.
  • Men and women age >=18 years
  • Ability and willingness of subject or legal guardian/representative to provide informed consent

Exclusion Criteria:

  • Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry
  • Screening HIV genotype obtained any time prior to study entry with any DRV RAM (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V)
  • Treatment within 30 days prior to study entry with immune modulators such as systemic steroids, interleukins, interferons, granulocyte colony-stimulating factor (G-CSF), erythropoietin, or any investigational therapy. NOTE: Subjects receiving stable physiologic glucocorticoid doses (defined as prednisone ≤10 mg/day [or equivalent] as a stable or tapering dose) are permitted. Subjects receiving corticosteroids for acute therapy for PCP or asthma exacerbation, or receiving a short course (defined as ≤2 weeks of pharmacologic glucocorticoid therapy) are permitted
  • Breast-feeding
  • Requirement for any medication that is prohibited with a study medication
  • Known allergy/sensitivity to study drugs or their formulations. A history of sulfa allergy is not an exclusion
  • Active drug or alcohol use or dependence that could interfere with adherence to study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00993148

United States, California
Quest Clinical Research
San Francisco, California, United States
United States, Florida
University of Miami
Miami, Florida, United States
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Chicago, Illinois, United States, 60612
United States, Nebraska
University of Nebraska
Omaha, Nebraska, United States
Sponsors and Collaborators
Northwestern University
Tibotec, Inc
Principal Investigator: Babafemi Taiwo, MD Northwestern University
  More Information

Responsible Party: Babafemi Taiwo, Associate Professor, Northwestern University Identifier: NCT00993148     History of Changes
Other Study ID Numbers: MIDAS
Study First Received: October 8, 2009
Results First Received: July 28, 2014
Last Updated: August 26, 2014

Keywords provided by Northwestern University:
Treatment naive

Additional relevant MeSH terms:
Communicable Diseases
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
CCR5 Receptor Antagonists processed this record on May 23, 2017